Skip to content
Agentic OS
Menu

Intelligence / Healthtech / New Clinical Trials / Editas Medicine, Inc.

Clinicaltrial registered26 Oct 2026

Editas Medicine, Inc.

26 Oct 2026: Trial registered · EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C). Recorded in the ClinicalTrials.gov (US National Library of Medicine).

View the source record

Posted
26 Oct 2026
Title
EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)
Conditions
Heterozygous Familial Hypercholesterolemia (HeFH)
Phase
Phase 1, Phase 2
Study Type
Interventional
Status
Not Yet Recruiting
Countries
Australia
Country
Australia
Reference
NCT07894887
Location
Australia
What this signal means

A new trial needs sites, patients, data capture, monitoring and regulatory partners for years.

  1. United States leads with 192 of 777, then China (171).
  2. 777 added in the 30 days to 18 Nov 2026.
Reach them with AOS

Find the decision makers at Editas Medicine, Inc.

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this clinical signal, for your approval.

Start free

More from Australia

New Clinical Trials

See all

Source: ClinicalTrials.gov (US National Library of Medicine), data to 18 Nov 2026. Trials first posted in the window whose lead sponsor is a company, worldwide. Device and diagnostic studies usually have no phase. AOS shows what the public record says; it does not verify or endorse the company.